The European Commission has adopted Implementing Regulation (EU) 2026/977, establishing harmonized and binding timelines for Notified Body conformity assessments under the MDR and IVDR. This episode details the new maximum timelines for key review stages—such as the 90-day limit for technical documentation assessment—and new rules for cost transparency. We explore how this regulation, adopted on May 4, 2026, provides greater predictability for manufacturers in their CE marking process, addressing long-standing industry concerns about inconsistent and lengthy review periods.

Key Questions:

- What is EU Implementing Regulation 2026/977 and why was it created?

- What are the new maximum timelines for Notified Body conformity assessments under the MDR and IVDR?

- How does the 90-day limit for technical documentation review impact CE marking strategy?

- What do the new rules on cost transparency mean for manufacturers?

- How can manufacturers leverage these changes to improve their product launch planning?

- What happens if a manufacturer's submission is incomplete and the review clock is stopped?

- How should regulatory teams adjust their internal processes in response to this regulation?

- What are the key obligations for Notified Bodies under these new rules?

Sources:

- https://www.medtecheurope.org/news-and-events/news/new-eu-rules-more-business-predictability-and-transparency-in-medtech-conformity-assessment/

- https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8924156/

- https://www.decomplix.com/medical-device-regulatory-affairs-news/

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex global markets. We help manufacturers adapt to new requirements like the EU's harmonized Notified Body timelines by developing efficient regulatory strategies and preparing high-quality technical dossiers to avoid delays. Our combination of local experts in over 30 markets and advanced AI technology streamlines the submission process, ensuring your products get to market faster. For support with your CE marking strategy or global expansion, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

The UK's MHRA has published draft medical device regulations set for 2026, introducing a new standalone framework for Great Britain. This episode breaks down the most significant change: the International Reliance pathway, which will leverage approvals from the US, Canada, and Australia to streamline UK market access. We cover the critical June 19, 2026, deadline for the industry impact survey, other key changes like UDI implementation and new rules for software, and provide practical steps for manufacturers to prepare for this new era of UK medical device regulation.

Key Questions:

- What is the new International Reliance pathway proposed by the UK MHRA?

- Which international approvals will be recognized under the new UK framework?

- What is the deadline for submitting feedback on the draft 2026 regulations?

- How will the new rules affect software as a medical device (SaMD)?

- What is the role of the UKCA mark in this new reliance model?

- Who is affected by these proposed regulatory changes?

- What practical steps should manufacturers take to prepare for 2026?

- How will the introduction of a UDI system impact device traceability in the UK?

Sources:

- https://www.hoganlovells.com/en/publications/uk-medical-devices-reform-mhra-publishes-draft-2026-regulations-and-launches-impact-survey

- https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8991557/

- https://www.nsf.org/knowledge-resources/mhra-reform-2026-new-requirements-medical-devices-great-britain

- https://www.arnoldporter.com/en/perspectives/publications/2026/05/mhra-publishes-draft-amendment-to-the-uk-medical-devices-regulations

- https://www.pinsentmasons.com/out-law/analysis/update-to-the-medical-devices-regulatory-regime-key-proposals-and-implications

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to navigate complex market changes like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, act as your local UK Responsible Person, and use advanced AI to compile and manage technical dossiers for UKCA submissions. We help you leverage the new International Reliance pathway by assessing your existing approvals and streamlining your path to market. Whether you're a startup or a multinational, we accelerate your access to over 30 global markets. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

In this episode, we break down Mexico's new comprehensive medical device labeling standard, NOM-137-SSA1-2025, published by the health regulator COFEPRIS. We explore the key changes from the previous 2008 version, including new definitions for 'component' and 'single-use device,' and the new mandate to include the intended use, manufacturing date, and catalog number directly on device labeling. We also discuss the critical compliance deadline of May 14, 2027, and outline practical steps that manufacturers must take during the one-year transition period to update their labels and Instructions for Use (IFU) to maintain market access in Mexico.

Key Questions:

- What are the most significant changes in Mexico's new medical device labeling standard, NOM-137-SSA1-2025?

- How do the new definitions for 'component' and 'single-use device' affect our products?

- What specific new information must be added to our device labels to comply with COFEPRIS?

- What is the final deadline for all devices on the Mexican market to meet these new requirements?

- How should we manage existing inventory with legacy labeling during the transition period?

- What are the potential consequences of non-compliance after May 14, 2027?

- What are the first steps our regulatory team should take to create a transition plan?

- Does the new standard impact the requirements for Instructions for Use (IFU) as well?

Sources:

- https://www.emergobyul.com/news/mexicos-cofepris-publishes-final-version-medical-device-labeling-standard

- https://www.pure-global.com/news-and-updates/medical-device-regulatory-news-and-updates

How Pure Global can help:

Pure Global helps MedTech and IVD companies access global markets faster. Our experts in Mexico can manage your transition to the new NOM-137-SSA1-2025 labeling standard, acting as your local representative and ensuring your technical dossiers are fully compliant. We use advanced AI to streamline document compilation and submission, reducing delays and costs. Whether you're a startup or a multinational, our end-to-end solutions cover regulatory strategy, quality assurance, and post-market surveillance to maintain your market presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

In this episode, we explore the U.S. FDA's significant new guidance on Human Factors Engineering (HFE) for medical devices. The host breaks down the new three-tiered, risk-based framework for HFE submissions, which impacts 510(k), De Novo, and PMA applications. We discuss the specific changes, who is most affected, the critical implementation deadline of January 1, 2027, and provide practical, actionable steps for regulatory and quality teams to ensure compliance and avoid submission delays.

Key Questions:

- What are the major changes in the FDA's new Human Factors Engineering guidance?

- How does the new three-tiered risk system classify medical devices for HFE submissions?

- Which types of devices will face the most scrutiny under the new framework?

- What is the critical deadline for adopting these new HFE requirements?

- What happens if my 510(k) or PMA submission doesn't meet the new HFE standards?

- How should I update my Usability Engineering File to comply?

- What are the first steps my team should take to perform a gap analysis?

- Does the new guidance change the requirements for summative usability testing?

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges, like the FDA's new HFE guidance. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for 510(k) and PMA submissions, minimizing delays. We act as your local representative and ensure your quality systems and clinical data meet international standards. Accelerate your global market access by contacting us at [email protected] or visiting https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode details the critical EUDAMED deadline of May 28, 2026, when four key modules become mandatory for medical device and IVD manufacturers in the EU. We explain the immediate legal obligation to register all new MDR and IVDR devices in the UDI/Devices module before market placement. We also cover the mandatory registration for actors—manufacturers, authorized representatives, and importers—and the separate deadline of November 28, 2026, for registering legacy devices and uploading certificates.

- What is the critical EUDAMED deadline on May 28, 2026?

- Which four EUDAMED modules are becoming mandatory?

- What is the new legal requirement for all new MDR and IVDR devices before they can enter the EU market?

- Which economic operators must register in the Actor module?

- Is there a different deadline for registering "legacy devices"?

- What are the requirements for uploading certificates from Notified Bodies?

- How does this change impact your company's EU market access strategy?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. With the EU's EUDAMED deadlines approaching, our expertise in regulatory strategy and technical dossier submission is crucial. We act as your local representative and use advanced AI to efficiently compile and manage your UDI/Device and Actor registrations, ensuring you meet the May 28, 2026, mandatory requirements without delay. Let us help you navigate these complex changes and maintain your market presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the future of the structural heart market, a key growth area in MedTech. We discuss the technological advancements in imaging, catheter tools, and procedural guidance that are shaping the industry. We analyze how leading companies like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific are moving beyond single implants to create comprehensive procedural ecosystems, and what this means for market leadership by 2026.

- Why is the structural heart market one of MedTech's most attractive growth arenas?

- How are advancements in imaging and catheters changing cardiac procedures?

- What does it mean to own the full "ecosystem" in structural heart therapy?

- Which companies are best positioned to dominate the market by 2026?

- How is the focus shifting from a single device to a complete procedural solution?

- What are the key differences between TAVR and TMVR procedures?

- What role will AI and advanced software play in the future of structural heart interventions?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. We help you develop regulatory strategies, prepare technical dossiers, and act as your local representative in over 30 markets. From market selection to post-market surveillance, our technology-driven solutions ensure efficiency and compliance. Whether you are a startup or a multinational enterprise, Pure Global provides scalable support to bring your innovations to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the imminent commercialization of Brain-Computer Interface (BCI) technology, moving it from a futuristic concept to a medical reality by 2026. We examine the four critical non-technical hurdles the industry must overcome for successful global market access: establishing clear clinical utility, navigating the complex reimbursement landscape with payers like CMS, addressing profound data privacy and security risks of neural data, and solving the ethical challenges of informed consent and long-term device support.

- Is 2026 the year Brain-Computer Interfaces become a commercial reality?

- What lessons can new neurotech companies learn from the commercial failure of the Argus II bionic eye?

- How can developers prove value to payers like Medicare and private insurers to secure reimbursement?

- What regulatory frameworks are needed to protect the privacy and security of sensitive neural data?

- Who is responsible for a patient's BCI implant after a clinical trial ends or a company fails?

- How does physician adoption impact the market access strategy for a novel medical device?

- What are the key ethical considerations for informed consent in invasive BCI surgery?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We combine local expertise in over 30 markets with advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and manage submissions. From initial market research to post-market surveillance, our integrated approach ensures your innovative products, including advanced neurotechnology, reach patients faster. Let us help you navigate the complexities of international approvals and maintain compliance. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the future of AI in healthcare, focusing on whether ambient documentation and AI-powered charting will become standard clinical infrastructure by 2026. We weigh the technology's potential to reduce physician burnout and improve data quality against the significant barrier of provider trust, particularly concerning the accuracy of AI-generated notes in high-stakes medical environments.

- Will ambient AI become a standard tool in most clinics by 2026?

- How does AI-powered charting aim to solve the physician burnout crisis?

- What are the primary accuracy concerns holding back provider adoption?

- Can AI-generated clinical notes be trusted for critical medical decisions?

- What regulatory hurdles must AI documentation software overcome to gain market access?

- How will technology vendors prove the reliability and safety of their AI scribes?

- What is the difference between ambient documentation and traditional dictation services?

As pioneers in AI-powered medical devices and software seek to enter new territories, navigating the regulatory landscape is critical. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging advanced AI tools to streamline global market access. We develop efficient regulatory strategies and manage technical dossier submissions to get your product approved faster. Whether you are a startup or a multinational enterprise, our global team provides the local expertise needed for success. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the critical challenge MedTech leaders face in 2026 regarding the safe implementation of AI chatbots in healthcare. We discuss how to develop a robust governance model that effectively balances the competing demands of innovation speed, user-friendliness, essential human oversight, and uncompromising patient safety to prevent misleading patients and clinicians.

- How can MedTech companies deploy AI chatbots without compromising patient safety?

- What does a balanced governance model for clinical AI look like in practice?

- What is the "human-in-the-loop" model and why is it essential for medical AI?

- How can organizations manage the pressure to innovate quickly while ensuring rigorous validation?

- What are the key regulatory and safety considerations for AI influencing care pathways?

- How should usability be designed to prevent over-reliance on AI by clinicians?

- What are the risks of AI "correctness drift" in a post-market setting?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. Our services cover the entire product lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance. By leveraging AI and a network of local experts in over 30 markets, we help you navigate complex regulatory landscapes efficiently. For help getting your medical device to market faster, contact us at [email protected], visit https://pureglobal.com/, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the significant market shift toward molecular and genetic diagnostics projected for 2026. We analyze the key drivers behind this trend and outline how MedTech and IVD companies can create value in high-growth areas like oncology, infectious disease, personalized medicine, and the development of integrated data platforms that provide actionable clinical insights.

- Why is diagnostic spending shifting dramatically towards molecular and genetic tests by 2026?

- What are the primary drivers making advanced genomic testing more accessible?

- How can MedTech companies create value in oncology beyond traditional diagnostics?

- What is the critical role of point-of-care molecular testing in managing infectious diseases?

- Why are integrated data platforms and AI becoming essential for the next wave of diagnostics?

- How does personalized medicine change the strategy for diagnostic companies?

- What are the opportunities in companion diagnostics and liquid biopsies?

- Is your company prepared to navigate the regulatory complexities of these advanced IVDs?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you access over 30 global markets. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and streamline submissions, minimizing costs and accelerating your time to market. Whether you're a startup or a multinational, our local experts provide the support needed to navigate complex international requirements for cutting-edge diagnostics. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.